Polypharmacy is common in the treatment of attention-deficit hyperactivity disorder (ADHD). However, the use of multiple drugs increases the risk of pharmacokinetic drug–drug interactions (DDIs) and subsequent adverse safety outcomes. Clinically relevant pharmacokinetic DDIs can be prevented by adjusting the dose of the ADHD drug or, if possible, by using an alternative drug that would not have a pharmacokinetic effect on the ADHD drug.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Mattingly GW, Wilson J, Ugarte L, et al. Individualization of attention-deficit/hyperactivity disorder treatment: pharmacotherapy considerations by age and co-occurring conditions. CNS Spectr. 2020. https://doi.org/10.1017/S1092852919001822.
Schoretsanitis G, de Leon J, Eap CB, et al. Clinically significant drug–drug interactions with agents for attention-deficit/hyperactivity disorder. CNS Drugs. 2019;33(12):1201–22.
Mazhar H, Foster BC, Necyk C, et al. Natural health product-drug interaction causality assessment in pediatric adverse event reports associated with attention-deficit/hyperactivity disorder medication. J Child Adolesc Psychopharmacol. 2020;30(1):38–47.
Childress AC, Sallee FR. Attention-deficit/hyperactivity disorder with inadequate response to stimulants: approaches to management. CNS Drugs. 2014;28(2):121–9.
Harstad EB, Weaver AL, Katusic SK, et al. ADHD, stimulant treatment, and growth: a longitudinal study. Pediatrics. 2014;134(4):e935–e944944.
Bolea-Alamanac B, Nutt DJ, Adamou M, et al. Evidence-based guidelines for the pharmacological management of attention deficit hyperactivity disorder: update on recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2014;28(3):179–203.
Subcommittee on Attention-Deficit/Hyperactivity D, Steering Committee on Quality I, Management, et al. ADHD: clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics. 2011;128(5):1007–222.
Bond DJ, Hadjipavlou G, Lam RW, et al. The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid attention-deficit/hyperactivity disorder. Ann Clin Psychiatry. 2012;24(1):23–37.
Spina E, Hiemke C, de Leon J. Assessing drug-drug interactions through therapeutic drug monitoring when administering oral second-generation antipsychotics. Expert Opin Drug Metab Toxicol. 2016;12(4):407–22.
Weiss M, Hechtman L, Adult ARG. A randomized double-blind trial of paroxetine and/or dextroamphetamine and problem-focused therapy for attention-deficit/hyperactivity disorder in adults. J Clin Psychiatry. 2006;67(4):611–9.
Vyvanse® (lisdexamfetamine dimesylate): US prescribing information. Lexington: Shire US Inc: 2017.
Schaller JL, Behar D. Carbamazepine and methylphenidate in ADHD. J Am Acad Child Adolesc Psychiatry. 1999;38(2):112–3.
Behar D, Schaller J, Spreat S. Extreme reduction of methylphenidate levels by carbamazepine. J Am Acad Child Adolesc Psychiatry. 1998;37(11):1128–9.
Wharton RN, Perel JM, Dayton PG, et al. A potential clinical use for methylphenidate with tricyclic antidepressants. Am J Psychiatry. 1971;127(12):1619–25.
Sauer JM, Ring BJ, Witcher JW. Clinical pharmacokinetics of atomoxetine. Clin Pharmacokinet. 2005;44(6):571–90.
Li A, Yeo K, Welty D, et al. Development of guanfacine extended-release dosing strategies in children and adolescents with ADHD using a physiologically based pharmacokinetic model to predict drug-drug interactions with moderate CYP3A4 inhibitors or inducers. Paediatr Drugs. 2018;20(2):181–94.
Intuniv® (guanfacine) extended-release tablets: US prescribing information. Lexington: Shire US Inc: 2019.
Kiechel JR, Lavene D, Guerret M, et al. Pharmacokinetic aspects of guanfacine withdrawal syndrome in a hypertensive patient with chronic renal failure. Eur J Clin Pharmacol. 1983;25(4):463–6.
The preparation of this review was not supported by any external funding.
Conflict of interest
EK and YAH are contracted or salaried employees of Adis International Ltd./Springer Nature and declare no relevant conflicts of interest.
About this article
Cite this article
Kim, E., Heo, Y. Consider clinically relevant pharmacokinetic drug interactions when co-prescribing drugs in attention-deficit/hyperactivity disorder. Drugs Ther Perspect (2020). https://doi.org/10.1007/s40267-020-00749-3